This study is testing a new approach for adults with bothersome tinnitus (ringing in the ears) that started after long-COVID or a COVID-19 vaccine, and hasn't improved with other treatments. All 20 participants will receive two treatments for 30 days: an ear solution containing dimethyl sulfoxide (DMSO), betahistine, dexamethasone, and lidocaine, and a skin cream with DMSO, levocarnitine, and N-acetylcysteine. The ear solution is used every four days, and the cream is applied daily around the ears and neck. The main goal is to see if at least half of the participants experience a 50% or more reduction in their Tinnitus Handicap Inventory (THI) score, which measures how much tinnitus affects their daily life.

Study design

This is a single-arm, open-label pilot study, meaning all 20 participants will receive the same treatments, and everyone involved will know what treatments are being given.

What's involved

You would receive an ear solution every four days for a total of 8 applications over 30 days, and apply a cream once daily at bedtime for 30 days.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at Day 30, which is the end of the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.